Checkpoint inhibitors are among the most promising therapeutic approaches for the treatment of a variety of cancers such as cervical cancer, leading to strong immune responses against tumor cells by blocking PD1/PD-L1 or TIM-3/Gal-9. This evidence concerns the gene CD274 and cervical cancer.